All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Two-year follow-up of KTE-X19 in adult patients with R/R B-ALL: ZUMA-3 trial
The updated findings from the ZUMA-3 trial demonstrate that with longer follow-up and a larger pooled data set, outcomes remained stable over time in adult patients with R/R...
Jun 27, 2022
|B-ALL
Hervé Dombret
"In partnership with the European School of Haematology, the ALL Hub will contribute to the dissemination of knowledge and favor fruitful translational discussions in the field of ALL."
Are you a healthcare professional? What is your speciality?
Please select or type your speciality
By sharing this information, you can help ensure we continue to develop content that is of most relevance for our audience.
Thank you for submitting.